Patterson R, Guest M, Shenouda M, Pareek V, Galloway K, Bucher O, Hebbard P, Nashed M. Predictors of residual disease after breast conservation surgery for ductal carcinoma in situ: A retrospective study.
J Cancer Res Ther 2024;
20:844-849. [PMID:
39023593 DOI:
10.4103/jcrt.jcrt_2657_22]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 01/12/2023] [Indexed: 07/20/2024]
Abstract
BACKGROUND
Breast-conserving therapy is the standard of care for ductal carcinoma in situ (DCIS). Debate on what constitutes a satisfactory margin persists. This study aimed to identify predictors of residual disease at re-excision.
METHODS
This is a population-based retrospective cohort study of women with DCIS who underwent a lumpectomy between 2007 and 2017 in Manitoba, with close (≤2 mm) or positive margins that led to re-excision.
RESULTS
The DCIS re-excision rate was 29.3% for 1001 patients. 63.2% of patients were found to have residual disease on re-excision. On univariable analysis, the size, margin status, number of positive margins, type of second surgery, and Van Nuys Prognostic Index score were associated with residual disease on re-excision. The size of DCIS and the number of positive margins remained statistically significant on multivariable analysis.
CONCLUSIONS
Re-excision should be rationalized by considering the predictors of residual disease in conjunction with other factors.
Collapse